AstraZeneca Pharma India liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

11.10×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.76×	1.76×	1.91×	2.61×	2.31×
0.72×	0.72×	1.13×	1.97×	1.81×
448	448	536	506	500
750	750	639	576	503

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

ASTRAZEN₹6,299.00

AstraZeneca Pharma India Limited

· Pharma & Health

₹ CrorePeersSANOFICONR PGHL SANOFI SENORES INNOVACAP MOREPENLAB IOLCP FDCMcap ₹15,748 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	11.10
Current Ratio	2.31	2.61	1.91	1.76	1.76
Quick Ratio	1.81	1.97	1.13	0.72	0.72
Cash, Equiv & ST Investments	500.3	505.6	536.1	447.7	447.7
Working Capital	503.1	575.6	639.4	750.4	750.4

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.